AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03754517 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RPR Titer
Description: RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
Study NCT02484209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 1500 mg daily for 16 weeks
Study NCT01065077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 150 µg/h during 48h
Study NCT01065077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 100 µg/h during 48h
Study NCT00337207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
Study NCT03565783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study NCT04657536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency fulguration equipment
Description: All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
Study NCT01464177 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic hypofractionated RT 5x5Gy
Description: Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization
Study NCT01464177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic hypofractionated RT 5x7Gy
Description: Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization.
Study NCT01065077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 50 µg/h during 48h
Study NCT01065077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of placebo during 48h
Study NCT02772159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Description: One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
Study NCT03330275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: JJVC senofilcon A-based contact lens with new UV-blocker
Study NCT03385226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
Study NCT03385226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 12Gy in 3 fractions
Study NCT01196026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: One or two intramuscular injections
Study NCT01196026 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™ Junior
Description: Two intramuscular injections
Study NCT00837213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide with clindamycin
Description: Benzoyl peroxide wash - Clindamycin foam
Study NCT00837213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide with clindamycin and doxycycline
Description: Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
Study NCT02855268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lademirsen (SAR339375)
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
Study NCT02855268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
Study NCT02396706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivy Leaves Cough Liquid
Study NCT02396706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03202563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg
Description: For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
Study NCT03202563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
Study NCT04239976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Assessment Test
Description: Undergo gait assessment test
Study NCT03202563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91
Study NCT03202563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diet/exercise questionnaire
Description: doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91
Study NCT03202563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System(CGMS)
Description: For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
Study NCT03202563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System(CGMS)
Description: For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
Study NCT03202563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
Study NCT03202563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
Study NCT01540357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based therapy
Description: Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
Study NCT01540357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment after waiting time
Description: Treatment was performed after completion of the active arm.
Study NCT01543074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BSE placebo
Description: 2 pills = 0 micromoles of Sulforaphane/day
Study NCT01543074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BSE placebo
Description: 2 pills = 0 micromoles of Sulforaphane/day
Study NCT01543074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic oil
Description: 1 pill = 30 mg garlic oil/day
Study NCT01543074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSE
Description: 2 pills = 200 micromoles of Sulforaphane/day
Study NCT01543074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Garlic Oil Placebo
Description: 1 pill = 0 mg garlic oil/day
Study NCT01543074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic Oil Placebo
Description: 1 pill = 0 mg garlic oil/day
Study NCT02351765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acelarin
Description: First-in-class nucleotide analogue
Study NCT02351765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum-compound chemotherapy drug
Study NCT02072265 — intervention group
Intervention type: DEVICE
Intervention: Infrared thermal images
Study NCT01034930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of dental implants
Description: Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
Study NCT01568840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation Group
Description: Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
Study NCT01568840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Segmental Exercises Group
Description: Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
Study NCT02345473 — intervention group
Intervention type: GENETIC
Intervention: Detection of circulating tumor cells in blood samples
Description: Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
Study NCT05565703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PARO Robotic Seal Intervention
Description: PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.
Study NCT05565703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
Study NCT04131946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-Based (Intervention Arm)
Description: Community dispensed FIT
Study NCT01295593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid and 2-chlorodeoxyadenosine
Description: VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
Study NCT04041154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Fatigue
Description: Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
Study NCT04041154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Fatigue
Description: Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
Study NCT04041154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewarding Stimuli
Description: Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
Study NCT00986843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM30181AK tablet + Irinotecan tablets
Description: HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
Study NCT04132310 — intervention group
Intervention type: OTHER
Intervention: N/A This is an observational study.
Description: This is an observational study.
Study NCT01749878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1500
Study NCT04657536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: promestriene vaginal soft capsules
Description: Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
Study NCT02256891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRFM
Study NCT02256891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Row
Study NCT01563575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fast-track implementation process
Description: Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
Study NCT02457533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle behavioral. Health plan, telephone support
Description: 'Lifestyle behavioral. Health plan, telephone support'
Study NCT00839293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Once, see arm description for more information
Study NCT04586803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Study NCT01489046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986001
Description: Capsules, Oral, 100 mg, Once daily, At least 48 weeks
Study NCT01489046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986001
Description: Capsules, Oral, 200 mg, Once daily, At least 48 weeks
Study NCT01489046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986001
Description: Capsules, Oral, 400 mg, Once daily, At least 48 weeks
Study NCT01489046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986001
Description: Capsules, Oral, 0 mg, Once daily, At least 48 weeks
Study NCT01489046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
Study NCT01489046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
Study NCT03330275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS
Description: senofilcon A
Study NCT01749878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT03330275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial ACUVUE OASYS and Spectacles
Description: Senofilcon A and Spectacles
Study NCT04239976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MC5-A Scrambler Therapy
Description: Undergo scrambler therapy
Study NCT04239976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04239976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Undergo quantitative sensory test
Study NCT04239976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02473549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TDCS
Description: Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
Study NCT02473549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal TDCS
Description: Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
Study NCT02473549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal TDCS
Description: Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
Study NCT00665327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
Study NCT00665327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
Study NCT02962440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
Study NCT02660489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC459
Study NCT02660489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02473549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
Study NCT00956527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified traditional martial arts training
Description: Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts.
Study NCT02641431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mapping/ablation
Description: Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
Study NCT02641431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ajmaline
Description: Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
Study NCT02641431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation
Description: Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.